Autoimmune Hepatitis: The Liver Disease Caused by Your Own Immune System

Autoimmune Hepatitis is a chronic inflammatory disease of the liver in which the immune system abnormally attacks the liver tissue. The immune system produces antibodies against liver cells and liver enzymes. T cells infiltrate liver tissue. The immune attack causes inflammation and damage to the liver. The damaged liver cells die. Scar tissue replaces dead liver cells. Over time, cirrhosis can develop if disease is not controlled. Autoimmune Hepatitis affects approximately one to two people per one hundred thousand worldwide. The disease is more common in women than men, affecting women approximately two to three times more frequently than men. The disease can develop at any age but typically develops in young to middle-aged adults. Some cases develop in children. Autoimmune Hepatitis is caused by abnormal immune activation against liver tissue. The exact trigger is not completely understood. Genetic predisposition appears important. Environmental factors including infections may trigger disease in susceptible people. The immune system produces antibodies against liver enzymes. Anti-smooth muscle antibodies develop in some patients. Anti-liver kidney microsomal antibodies develop in others. Anti-nuclear antibodies develop in some. These autoimmune antibodies attack liver tissue. T cells infiltrate the liver. Inflammatory cytokines cause inflammation. The liver becomes inflamed. Hepatocytes, the liver cells, are damaged. Liver cell death occurs. Fibrosis begins. Scar tissue replaces damaged liver tissue. Progressive fibrosis leads to cirrhosis. Cirrhosis is permanent scarring throughout the liver. Cirrhosis causes liver failure. Autoimmune Hepatitis is classified into types based on antibody pattern. Type 1 autoimmune hepatitis has anti-smooth muscle antibodies and anti-nuclear antibodies. Type 1 is the most common. Type 2 autoimmune hepatitis has anti-liver kidney microsomal antibodies. Type 2 is less common. Type 3 has anti-soluble liver antigen antibodies. Type 3 is rare. The type classification helps with diagnosis and may influence prognosis. Early diagnosis and appropriate treatment are crucial for controlling inflammation and preventing cirrhosis. With modern treatments, remission is achievable in many patients. Understanding Autoimmune Hepatitis helps with early recognition and appropriate management to prevent progressive liver damage and failure.

How Does Immune Attack on Liver Tissue Cause Autoimmune Hepatitis?

To understand Autoimmune Hepatitis, we need to learn about the liver and the immune system. The liver is the largest internal organ. The liver performs multiple vital functions. The liver produces proteins. The liver metabolizes drugs. The liver stores vitamins and minerals. The liver produces bile for fat digestion. The liver detoxifies harmful substances. Hepatocytes are the functional cells of the liver. Hepatocytes perform the vital liver functions. Loss of hepatocytes causes loss of liver function. In Autoimmune Hepatitis, the immune system becomes abnormally activated against the liver. B cells produce autoimmune antibodies. Anti-smooth muscle antibodies attack smooth muscle components in the liver. Anti-liver kidney microsomal antibodies attack liver enzyme components. Anti-nuclear antibodies attack nuclear components. These antibodies bind to liver cells. The antibodies activate complement. Complement causes inflammation and cell death. The antibodies also activate antibody-dependent cellular cytotoxicity. Natural killer cells attack antibody-coated liver cells. T cells infiltrate liver tissue. CD8 positive T cells directly attack hepatocytes. CD4 positive T cells help coordinate immune response. The infiltrating T cells produce inflammatory cytokines. Interleukin-2, interleukin-6, TNF-alpha are produced. These inflammatory cytokines activate more immune cells. The inflammation spreads throughout the liver. Hepatocytes are progressively damaged and destroyed. Inflammatory cells accumulate in portal regions. The portal regions are areas between liver lobules. Portal inflammation is characteristic of autoimmune hepatitis. The inflammatory process is chronic. Without treatment, inflammation persists. Progressive hepatocyte death occurs. Progressive fibrosis develops. Stellate cells in the liver become activated. Activated stellate cells produce collagen. Collagen accumulates in the liver. Fibrosis progresses. Portal-to-portal fibrosis. Portal-to-central fibrosis. Bridging fibrosis. Eventually, cirrhosis develops. Cirrhosis is characterized by widespread fibrosis throughout the liver. The liver becomes hardened and scarred. Liver function progressively declines. The inflammatory process affects not just hepatocytes but also the bile duct system. Bile duct inflammation can occur. Some patients have overlap features with primary biliary cirrhosis or primary sclerosing cholangitis. The combination of hepatocyte damage and bile duct inflammation creates a complex disease. The systemic nature of the immune activation can affect other organs. Other autoimmune diseases may coexist. Thyroiditis. Celiac disease. Ulcerative colitis. The association with other autoimmune diseases suggests a systemic immune disorder. Understanding the inflammatory mechanisms has led to development of immunosuppressive treatments.

What Are the Main Symptoms and Signs of Autoimmune Hepatitis?

Autoimmune Hepatitis causes variable symptoms depending on disease severity and stage. Some people have no symptoms initially. Others have prominent symptoms. The symptoms develop gradually in most cases. Fatigue is very common. Profound exhaustion. Systemic inflammation causes fatigue. Fatigue may be the primary complaint. Fatigue is often severe and disabling. Fatigue limits activity and work capacity. Abdominal pain is common. Right upper quadrant pain. Liver pain from inflammation. Soreness over liver region. Pain with palpation. The pain may be mild or severe. Joint pain and swelling occur in many. Arthralgia. Arthritis. Hands, wrists, and knees commonly affected. Non-erosive arthritis. Joints usually not permanently damaged. However, pain can be significant. Myalgia, or muscle pain, may occur. Muscle aches. Generalized body aches. Inflammation causes muscle pain. Jaundice develops in some. Yellowing of skin and sclera. Bilirubin elevation. Indicates significant liver dysfunction. Dark urine from bilirubin excretion. Pale stool from reduced bile flow. Jaundice indicates more advanced disease. Itching, or pruritus, occurs in some. Severe itching. Bile acid accumulation in skin. Very bothersome symptom. Impacts quality of life. Sleep disruption from itching. Nausea and vomiting occur in some. Appetite loss. Difficulty with food intake. Weight loss from reduced appetite. Abdominal bloating. Abdominal fullness. Gas and bloating. Diarrhea or constipation. Gastrointestinal symptoms variable. Fever may occur. Low-grade fever. Indicates active inflammation. Fever resolves with disease control. Amenorrhea in women. Loss of menstrual periods. Hormonal disruption from liver disease. Reversible with disease control. Spider angiomas develop. Small dilated blood vessels. Radiating pattern. Appear on face, chest, hands. Indicate portal hypertension. Sign of significant liver disease. Palmar erythema. Redness of palms. Vasodilation from liver disease. Sign of liver dysfunction. Ascites develops. Abdominal fluid accumulation. Abdominal swelling and distention. Indicates portal hypertension. Sign of cirrhosis. Serious complication. Edema of legs develops. Swelling of ankles and legs. Fluid retention. Indicates advanced liver disease. Hepatomegaly occurs. Liver enlargement. Palpable below rib cage. Tenderness. Indicates inflammation and congestion. Splenomegaly occurs. Spleen enlargement. From portal hypertension. Palpable below rib cage. Encephalopathy can develop. Confusion. Mental slowness. Personality changes. Sleep disturbance. Indicates advanced liver disease. Very serious symptom. Variceal bleeding risk. Esophageal varices from portal hypertension. Hematemesis, or vomiting blood. Melena, or black tarry stools. Life-threatening hemorrhage. Medical emergency. The symptoms vary widely. Some have mild symptoms for years. Others develop severe symptoms rapidly. Early symptoms often nonspecific. Fatigue and mild abdominal discomfort. Progressive symptoms indicate progressive disease. Jaundice and ascites indicate advanced disease. Early diagnosis prevents progression to advanced disease.

How is Autoimmune Hepatitis Detected and Diagnosed?

Autoimmune Hepatitis is diagnosed through a combination of clinical findings and specific laboratory and imaging tests. Early diagnosis is important for preventing progression to cirrhosis. Clinical history is important. Fatigue and abdominal discomfort. Joint pain. Systemic symptoms. Progressive symptoms. Risk factors for autoimmune disease. Female gender. Younger age. Family history of autoimmune disease. Coexisting autoimmune diseases. Physical examination reveals characteristic findings. Jaundice if present. Hepatomegaly. Splenomegaly. Spider angiomas if portal hypertension. Palmar erythema if liver disease. Ascites if advanced disease. Laboratory tests are crucial. Liver function tests. Aspartate aminotransferase, or AST. Alanine aminotransferase, or ALT. These liver enzymes are markedly elevated. AST and ALT elevation indicates hepatocyte damage. The degree of elevation may correlate with disease severity. However, not always. Some have mild elevation with significant inflammation. Alkaline phosphatase. Gamma-glutamyl transferase, or GGT. These cholestasis markers. Mildly elevated in autoimmune hepatitis. Alkaline phosphatase disproportionately elevated suggests bile duct involvement. Bilirubin. Total and direct bilirubin. Elevated if jaundice present. Indicates liver dysfunction. Albumin. Synthesized by liver. Low albumin indicates significant liver dysfunction. Prothrombin time, or PT. INR, or international normalized ratio. PT/INR prolonged if liver dysfunction. Indicates impaired clotting factor synthesis. Significant prolongation indicates advanced liver disease. Platelet count. Low platelets suggest portal hypertension. Hemoglobin. Anemia common in chronic liver disease. Autoimmune antibodies. Anti-smooth muscle antibodies. Present in type 1 autoimmune hepatitis. Nearly eighty percent of type 1 patients. Anti-liver kidney microsomal antibodies. Present in type 2 autoimmune hepatitis. Type 2 is less common. Anti-soluble liver antigen antibodies. Present in type 3. Very rare. Antinuclear antibodies. Present in some patients. Helps classify disease. Anti-mitochondrial antibodies. Usually negative. Positive suggests primary biliary cirrhosis. Helps distinguish from other liver disease. Rheumatoid Factor. Usually negative. Anti-CCP antibodies. Usually negative. Negative RF and anti-CCP help exclude rheumatoid arthritis. Immunoglobulin levels. IgG often elevated. Elevated IgG supports diagnosis. Immunoglobulin G elevation is characteristic. Albumin-bilirubin ratio. Helps assess severity. Liver ultrasound. Assesses liver size. Assesses liver echotexture. Assesses for cirrhosis. Looks for portal hypertension. Spleen size. Ascites. Doppler ultrasound assesses portal vein patency. Normal or fatty infiltration versus cirrhosis. Elastography. Transient elastography measures liver stiffness. Indicates degree of fibrosis. Non-invasive assessment of cirrhosis. FibroScan. Acoustic radiation force impulse. Liver biopsy is gold standard. Confirms diagnosis definitively. Shows inflammatory infiltrates. Portal inflammation. Interface hepatitis. Hepatocyte necrosis. Degree of fibrosis. Stages from 0 to 4. Stage 4 is cirrhosis. Biopsy helps assess severity. Guides treatment decisions. However, biopsy invasive. Not always necessary if clinical and laboratory features typical. CT or MRI if cirrhosis suspected. Detailed imaging. Assesses for cirrhosis. Assesses for complications. Portal hypertension features. The combination of clinical presentation with marked elevation of transaminases, elevated immunoglobulin G, positive autoimmune antibodies, and characteristic liver biopsy findings confirms diagnosis. Early diagnosis allows early treatment. Diagnostic delay allows progression to fibrosis and cirrhosis.

What Health Complications Do People with Autoimmune Hepatitis Face?

People with Autoimmune Hepatitis face serious complications from progressive liver inflammation and fibrosis. The complications depend on disease severity and disease control. Cirrhosis is the major complication. Progressive fibrosis leads to cirrhosis. Cirrhosis is permanent scarring throughout the liver. Cirrhosis is irreversible. Once cirrhosis develops, it cannot be cured. However, disease progression may be halted with treatment. Liver function progressively declines. The liver cannot perform vital functions. Cirrhosis causes multiple complications. Portal hypertension. Portal vein pressure elevation. Collateral vessel formation. Esophageal varices. Gastric varices. Ascites. Splenomegaly. Portal hypertension causes life-threatening complications. Variceal bleeding. Esophageal varices rupture. Massive upper gastrointestinal hemorrhage. Hematemesis. Melena. Hypovolemic shock. Mortality high without urgent treatment. Hepatic encephalopathy. Ammonia accumulation in blood. Toxic effects on brain. Confusion. Memory loss. Personality changes. Sleep disturbance. Asterixis, or flapping tremor. Coma. Very serious complication. Reflects advanced liver disease. Hepatorenal syndrome. Renal failure in liver disease. Vasodilation of splanchnic vessels. Reduced renal perfusion. Acute kidney injury. Oliguria. Azotemia. Life-threatening emergency. Spontaneous bacterial peritonitis. Infection of ascitic fluid. Fever. Abdominal pain. Peritonitis signs. Sepsis. High mortality. Requires emergency treatment. Hepatic hydrothorax. Fluid accumulation in pleural space. Respiratory compromise. Shortness of breath. Hypoxemia. Requires thoracentesis or treatment. Ascites. Abdominal fluid accumulation. Abdominal distention. Discomfort. Functional limitation. Mobility impairment. Increased intra-abdominal pressure. Portal hypertension. Hepatic decompensation. Cholestasis. Bile flow obstruction. Jaundice. Pruritus. Dark urine. Pale stool. Bilirubin accumulation. Coagulopathy. Impaired clotting factor synthesis. Prolonged PT/INR. Bleeding risk. Easy bruising. Epistaxis. Spontaneous bleeding. Hemorrhage. Thrombocytopenia. Low platelet counts. From bone marrow suppression and splenic sequestration. Bleeding risk. Bruising. Petechiae. Anemia. From chronic disease. Blood loss from variceal bleeding. Hemolysis. Fatigue. Transfusion requirements. Malnutrition. Inadequate hepatic synthesis. Malabsorption. Lactose intolerance. Fat-soluble vitamin deficiency. Vitamin A, D, E, K deficiency. Osteoporosis from vitamin D deficiency. Hepatic osteodystrophy. Bone disease. Fracture risk. Hepatocellular carcinoma risk. Cirrhosis increases HCC risk. Requires surveillance. Ultrasound and AFP monitoring. HCC has poor prognosis. Prevention through disease control crucial. Lipid abnormalities. Cholesterol elevation. Abnormal lipid metabolism. Metabolic syndrome. Diabetes risk. Cardiovascular disease risk. Overlapping syndromes. Overlap with primary biliary cirrhosis. Overlap with primary sclerosing cholangitis. Overlap features create more complex disease. Worse prognosis. Other autoimmune disease complications. Thyroid disease. Celiac disease. Ulcerative colitis. Rheumatoid arthritis. Management of coexisting autoimmune diseases necessary. Depression and psychological impact. Chronic progressive disease. Uncertainty about prognosis. Fear of liver failure. Depression common. Anxiety about complications. Grief about functional limitations. Mental health support important. Without early diagnosis and appropriate treatment, complications are serious and potentially life-threatening. With early treatment and good disease control, many complications can be prevented.

What Treatments Help People with Autoimmune Hepatitis?

Treatment for Autoimmune Hepatitis focuses on suppressing immune activation and preventing progression to cirrhosis. Early treatment is crucial for preventing permanent liver damage. Corticosteroids suppress immune activation. Prednisone is standard. Initial high-dose prednisone. Suppresses inflammation rapidly. Liver enzyme levels decrease. Bilirubin decreases. Symptoms improve. Gradual tapering over months. Tapering too rapidly causes flare. Low-dose maintenance therapy often necessary. Many require continued corticosteroid therapy long-term. Corticosteroid side effects require management. Osteoporosis. Infection risk. Diabetes. Hypertension. Weight gain. Mood disturbance. Azathioprine allows corticosteroid dose reduction. Immunosuppressive agent. Used with corticosteroids. Allows lower corticosteroid doses. Reduces long-term corticosteroid side effects. Benefits most patients. Requires monitoring for toxicity. Mycophenolate mofetil. Immunosuppressive agent. Used with corticosteroids. Alternative to azathioprine. May be better tolerated. Effective for disease control. Mercaptopurine. Immunosuppressive agent. Alternative to azathioprine. Some benefit in refractory disease. Methotrexate. Immunosuppressive agent. Some benefit reported. Less studied than azathioprine. Cyclosporine. Immunosuppressive agent. Used for steroid-refractory disease. Potent immunosuppression. Requires monitoring. Tacrolimus. Calcineurin inhibitor. Used for refractory disease. Alternative for steroid-intolerant patients. Mycophenolic acid. Immune modulation. Used for refractory disease. Rituximab targets B cells. B cell depletion. Used for refractory disease. Shows promise in clinical trials. TNF inhibitors. Limited benefit. Some use in refractory disease. Not first-line therapy. IL-6 inhibitors. Tocilizumab. May help refractory disease. Shows promise. Ursodeoxycholic acid. Bile acid. Supports liver health. May help cholestasis. Used as adjunctive therapy. Reduces cholestasis markers. Better tolerated. Often continued long-term. Antioxidants. N-acetylcysteine. May provide liver protection. Some benefit reported. Supportive therapy. Adequate nutrition. Protein adequate. Avoid excess sodium. Fluid restriction if ascites. Diuretics for ascites management. Spironolactone. Furosemide. Manages fluid overload. Portal hypertension management. Beta-blockers reduce portal pressure. Propranolol. Carvedilol. Reduces variceal bleeding risk. Prophylaxis with beta-blockers. Endoscopic variceal ligation if varices. Prevents variceal bleeding. Therapeutic intervention if bleeding. Encephalopathy management. Lactulose therapy. Reduces ammonia. Rifaxomicin. Non-absorbed antibiotic. Reduces ammonia-producing bacteria. Zinc supplementation. Supports ammonia metabolism. Protein restriction if severe encephalopathy. However, adequate protein important for liver. Balanced approach. Monitoring for complications. Regular liver ultrasound. Assess for cirrhosis. Assess for HCC if cirrhosis. Alpha-fetoprotein monitoring if cirrhosis. Surveillance for hepatocellular carcinoma. Upper endoscopy screening. Screen for esophageal varices. Treat if present. Ascites monitoring. Paracentesis if therapeutic or diagnostic. Kidney function monitoring. Watch for hepatorenal syndrome. With appropriate early treatment with corticosteroids and azathioprine or mycophenolate mofetil, most patients achieve remission or low disease activity. Liver function improves. Symptoms resolve. Progression to cirrhosis prevented.

Living with Autoimmune Hepatitis

Living with Autoimmune Hepatitis requires ongoing immunosuppressive treatment, regular monitoring, lifestyle modifications, and psychological adjustment to a chronic liver disease. For people newly diagnosed with Autoimmune Hepatitis, the diagnosis can be frightening. Learning about a disease affecting vital liver function is alarming. However, understanding that effective treatments exist and remission is achievable offers hope. Patient education about Autoimmune Hepatitis, treatment options, and disease course helps people understand their condition. Understanding importance of early treatment and compliance is crucial. Medication compliance is absolutely essential. Taking corticosteroids as prescribed. Following tapering schedule carefully. Azathioprine or mycophenolate compliance essential. Stopping medications allows disease reactivation. Regular monitoring for medication side effects. Corticosteroid toxicity. Azathioprine toxicity. Liver function monitoring. Regular liver enzyme testing. Bilirubin monitoring. PT/INR monitoring. Guides treatment adjustments. Assessment of disease activity. Titers of autoimmune antibodies. May fluctuate with disease activity. Ultrasound monitoring. Assess for cirrhosis progression. Assess for portal hypertension features. Assess for hepatocellular carcinoma if cirrhosis. Work and activity adjustments may become necessary. Severe fatigue may limit work capacity. Abdominal pain may limit activity. Some people need flexible work schedules for medical appointments. Some need reduced work hours due to fatigue. Severe disease may require disability. Disability support available. School adjustments for school-age children. Fatigue affecting school attendance. Abdominal pain affecting physical education. Frequent medical appointments. Educational accommodations. School counselor support. Nutrition management. Adequate protein supports liver health and function. However, excess protein avoided if encephalopathy present. Balanced diet. Adequate calories. Vitamins and minerals. Fat-soluble vitamin supplementation. Vitamin D supplementation important. Prevents osteoporosis. Calcium supplementation. Bone health. Reduce salt intake. Reduces ascites and portal hypertension. Limit fluid if ascites present. No alcohol. Alcohol is toxic to liver. Absolutely avoid. Alcohol worsens liver disease. Hepatotoxic medications avoided. NSAIDs avoided. Can worsen liver disease. Acetaminophen used with caution. Avoid excessive doses. Consult physician about all medications. Stress management reduces disease activity. Stress appears to trigger flares. Meditation and relaxation. Yoga. Regular moderate exercise. Improves overall health. Reduces stress. Supports weight management. Mental health support crucial. Depression common. Anxiety about disease progression. Fear of liver failure. Counseling helps. Antidepressants may be necessary. Support groups. Connect with others. Share experiences. Coping strategies. Online communities. Dating and relationships affected. Fatigue affects intimacy. Abdominal discomfort affects activity. Sexual dysfunction from disease or medications. Communication helps partners understand. Pregnancy possible but requires medical planning. Disease activity may change during pregnancy. Some medications safe, others not. Close medical monitoring essential. Risk of complications during pregnancy. Preeclampsia. Liver decompensation. Regular obstetric and hepatology follow-up. Breastfeeding usually safe with most medications. Social support from family and friends. Family education about disease. Understanding fatigue and limitations. Support with activity modifications. Emotional support. Regular medical follow-up. Hepatology follow-up crucial. Regular assessment of liver function. Regular assessment of disease activity. Regular monitoring for complications. Treatment adjustments based on response. Monitoring for adverse effects. With appropriate early aggressive immunosuppressive treatment, regular liver monitoring, activity modification within tolerance, stress management, adequate nutrition, alcohol avoidance, psychological support, family and social support, and regular medical follow-up, most people with Autoimmune Hepatitis can achieve remission or good disease control and maintain reasonable quality of life despite the serious nature of this progressive liver disease.

Frequently Asked Questions About Autoimmune Hepatitis

FAQ 1: Is Autoimmune Hepatitis the same as Viral Hepatitis? No, Autoimmune Hepatitis and Viral Hepatitis are different diseases. Viral Hepatitis is caused by viral infection. Hepatitis A, B, C, D, E viruses. These are contagious. Autoimmune Hepatitis is caused by immune attack. Not contagious. Not caused by virus. Caused by abnormal immunity. Autoimmune Hepatitis requires immunosuppression. Viral Hepatitis treatment depends on virus type. The distinction is important for treatment. They have different causes and treatments.

FAQ 2: Can Autoimmune Hepatitis be cured? Autoimmune Hepatitis cannot be completely cured. The underlying autoimmune process cannot be reversed. However, remission is achievable. Complete remission where disease is inactive. Some achieve complete remission. Others maintain low disease activity. Complete remission on therapy is possible. However, relapse risk if therapy stopped. Long-term therapy often necessary. With appropriate treatment, quality of life improves. Most achieve good symptom control.

FAQ 3: What is the life expectancy for people with Autoimmune Hepatitis? Life expectancy varies. Early diagnosis improves prognosis. With early treatment, most achieve good long-term survival. Five-year survival approximately ninety percent if diagnosed early. Ten-year survival approximately eighty percent if diagnosed early. Progression to cirrhosis decreases survival. Cirrhosis-related complications affect longevity. However, with modern treatment, life expectancy improves. Most live normal or near-normal lifespans.

FAQ 4: Can Autoimmune Hepatitis cause liver failure? Yes, untreated Autoimmune Hepatitis can progress to cirrhosis and liver failure. Untreated disease causes progressive liver damage. Progressive fibrosis. Eventually cirrhosis. Cirrhosis causes liver failure. Liver failure is life-threatening. However, early diagnosis and treatment prevent this progression. Most never reach liver failure if treated appropriately. Early treatment saves lives and preserves liver function.

FAQ 5: Are there new treatments being developed for Autoimmune Hepatitis? Yes, ongoing research into improved treatments. Better understanding of immune mechanisms. JAK inhibitors being studied. IL-6 inhibitors showing promise. B cell targeted therapies being studied. Gene therapy approaches being researched. Biomarker research identifying treatment responders. Clinical trials of new medications continue. As new treatments develop, outcomes improve. Better disease control achievable.

References and Further Reading

For more information about Autoimmune Hepatitis, you can visit several trusted and authoritative sources providing detailed information for patients and families dealing with this chronic liver disease. The World Health Organization at WHO.int provides comprehensive information about Autoimmune Hepatitis and autoimmune liver diseases. The American Association for the Study of Liver Diseases at AASLD.org offers clinical resources and patient education about liver diseases including Autoimmune Hepatitis. The Autoimmune Hepatitis Group International at AIHGlobal.org provides patient education and support for those with Autoimmune Hepatitis. The American College of Gastroenterology at ACG.care provides resources for gastrointestinal and liver diseases. MedlinePlus, a service of the National Library of Medicine at MedlinePlus.gov, has detailed medical information about Autoimmune Hepatitis written in language that patients and families can easily understand without specialized medical knowledge. The five main reference links are: 1) WHO.int – Autoimmune Hepatitis, 2) American Association for the Study of Liver Diseases, 3) Autoimmune Hepatitis Group International, 4) American College of Gastroenterology, and 5) MedlinePlus – Autoimmune Hepatitis.

Disclaimer

This article adapts publicly available information from WHO’s Autoimmune Hepatitis and liver disease information pages. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. If you or someone you know has been diagnosed with Autoimmune Hepatitis or shows signs of this condition including fatigue, abdominal pain, jaundice, dark urine, pale stool, pruritus, arthralgia, or other symptoms, please consult immediately with qualified healthcare professionals, hepatologists, and liver disease specialists for proper diagnostic evaluation with liver function tests, autoimmune antibody testing, immunoglobulin G testing, and liver biopsy if appropriate, and for appropriate early aggressive immunosuppressive treatment planning with corticosteroids and azathioprine or mycophenolate mofetil. Early diagnosis and early aggressive treatment significantly slow disease progression and prevent cirrhosis and liver failure. For more information, visit WHO.int and ObserverVoice.com.